Angiotensin‐converting enzyme gene rs4343 polymorphism increases susceptibility to migraine

Abedin-Do, Atieh; Pouriamanesh, Sara; Kamaliyan, Zeeba; Mirfakhraie, Reza

doi:10.1111/cns.12712

Cited by 14 publications

(11 citation statements)

References 9 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of AT1 receptor blockers, such as telmisartan, have shown benefits in prophylactic treatment of migraine 8,28 . Abedin‐Do et al also observed association between ACE gene rs4343 polymorphism and susceptibility to migraine 13 . Previously, Fusayasu et al showed increased ACE activity in migraine patients compared to controls, and correlation between SP levels and ACE activity 18 .…”

Section: Discussionmentioning

confidence: 99%

“…Clinical trials with angiotensin II type 1 (AT1) receptor blockers, such as candesartan, olmesartan, and telmisartan, and angiotensin‐converting enzyme (ACE) inhibitors, such as lisinopril, had promising results in the prophylaxis of migraine, being effective in reducing the frequency and/or severity of migraine attacks 8‐12 . ACE gene rs4343 polymorphism has also been associated with increased susceptibility to migraine 13 . However, the mechanisms underlying the positive effects of RAS modulation in migraine treatment remain to be elucidated.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Altered Serum Levels of Renin‐Angiotensin System Markers in Migraine

et al. 2020

View full text Add to dashboard Cite

Objective.-To compare the serum levels of renin-angiotensin system (RAS) components between patients with migraine and healthy controls, and to evaluate whether these levels are associated with migraine severity. We hypothesized that migraine would be associated with the activation of the inflammatory arm of the RAS, possibly leading to increased levels of angiotensin (Ang) II. Background.-Recent studies have proposed the use of drugs that interfere with RAS, a hormonal system primarily implicated in blood pressure regulation, as a prophylactic strategy for migraine. However, no previous studies have directly assessed RAS components in migraine. Methods.-This was a cross-sectional study involving 30 patients with episodic migraine who were in the interictal period and 20 healthy controls. This study was conducted at Hospital das Clínicas (Universidade Federal de Minas Gerais, Belo Horizonte, Brazil) outpatient clinic. Headache severity was evaluated using the Headache Impact Test, version 6 (HIT-6) and the Migraine Disability Test (MIDAS) questionnaires. Given that migraine is comorbid with mood disorders, depressive and anxious symptoms were evaluated using the Beck Anxiety and Depression Inventories (BDI and BAI), respectively. Clinical and demographic data were also collected. Serum levels of angiotensin-converting enzyme (ACE), ACE2, Ang II, and Ang (1-7) were measured by enzyme-linked immunosorbent assay. Results.-Patients with migraine and controls were comparable in age, body mass index, blood pressure, and depressive and anxious symptoms. Patients with migraine showed lower levels of ACE [

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Altered Serum Levels of Renin‐Angiotensin System Markers in Migraine

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It has been reported that the rs4343, rs4291, and also ACE I/D polymorphism affected the activity of this enzyme and the level of Ang II [ 75 , 76 ]. The rs4343 (G >A) ACE polymorphism is involved in hypertension, left ventricular hypertrophy, migraine, and coronary artery diseases [ 77 ]. Insertion/deletion (I/D) ACE polymorphism was associated with cardiovascular disease in which the D allele increased risk of cardiovascular disease.…”

Section: Synaptic/neuronal Activitymentioning

confidence: 99%

Genetic and molecular biology of autism spectrum disorder among Middle East population: a review

et al. 2021

View full text Add to dashboard Cite

Background Autism spectrum disorder (ASD) is a neurodevelopmental disease, characterized by impaired social communication, executive dysfunction, and abnormal perceptual processing. It is more frequent among males. All of these clinical manifestations are associated with atypical neural development. Various genetic and environmental risk factors are involved in the etiology of autism. Genetic assessment is essential for the early detection and intervention which can improve social communications and reduce abnormal behaviors. Although, there is a noticeable ASD incidence in Middle East countries, there is still a lack of knowledge about the genetic and molecular biology of ASD among this population to introduce efficient diagnostic and prognostic methods. Main body In the present review, we have summarized all of the genes which have been associated with ASD progression among Middle East population. We have also categorized the reported genes based on their cell and molecular functions. Conclusions This review clarifies the genetic and molecular biology of ASD among Middle East population and paves the way of introducing an efficient population based panel of genetic markers for the early detection and management of ASD in Middle East countries.

show abstract

“…Furthermore, angiotensin II receptor-antagonists are found to display a lower effect for MTA and MO patients with rs11172113, whereas alleles rs6790925 displays a nominal association with a higher effect in patients with “all migraine” and in MO [ 52 ]. Finally, anti-epileptic prophylactic medication has a lower effect in MO patients with rs2651899 allele, whereas rs10504861 is nominally associated with a higher effect in “all migraine” patients [ 53 ]. Migraineurs would benefit significantly from individualized prophylactic therapy, since every drug must go through three months of “trial and error” before demonstrating its efficacy.…”

Section: Genetic Polymorphisms and Gene Products Influence On Painmentioning

confidence: 99%

The Role of Genetic Polymorphisms in Chronic Pain Patients

Knežević

Tverdohleb

Knezevic

et al. 2018

IJMS

View full text Add to dashboard Cite

It is estimated that the total annual financial cost for pain management in the U.S. exceeds 100 billion dollars. However, when indirect costs are included, such as functional disability and reduction in working hours, the cost can reach more than 300 billion dollars. In chronic pain patients, the role of pharmacogenetics is determined by genetic effects on various pain types, as well as the genetic effect on drug safety and efficacy. In this review article, we discuss genetic polymorphisms present in different types of chronic pain, such as fibromyalgia, low back pain, migraine, painful peripheral diabetic neuropathy and trigeminal neuralgia. Furthermore, we discuss the role of CYP450 enzymes involved in metabolism of drugs, which have been used for treatment of chronic pain (amitriptyline, duloxetine, opioids, etc.). We also discuss how pharmacogenetics can be applied towards improving drug efficacy, shortening the time required to achieve therapeutic outcomes, reducing risks of side effects, and reducing medical costs and reliance upon polypharmacy.

show abstract

Angiotensin‐converting enzyme gene rs4343 polymorphism increases susceptibility to migraine

Cited by 14 publications

References 9 publications

Altered Serum Levels of Renin‐Angiotensin System Markers in Migraine

Altered Serum Levels of Renin‐Angiotensin System Markers in Migraine

Genetic and molecular biology of autism spectrum disorder among Middle East population: a review

The Role of Genetic Polymorphisms in Chronic Pain Patients

Contact Info

Product

Resources

About